Discovery: Colon Cancer’s Evasion of the Immune System’s Defense Barrier
A study conducted in the United Kingdom has shed light on how colon cancer affects the immune system. The research, conducted by the University of Glasgow in partnership with the Beaston Cancer Research Institute, focused on “gamma delta T” immune cells that are active in the epithelial tissue surrounding the intestines, where colon cancer originates.
The study revealed that the tumor in the colon alters the genetic code of gamma delta T cells, which are responsible for fighting harmful organisms in the body. This alteration leaves the immune system vulnerable to the cancer cells, as the T cells are unable to recognize the presence of the cancerous tissue.
The researchers aim to prevent this “blindness” in the immune cells by understanding how colon cancer rewrites the T cells’ genetic code. By developing a drug that can reverse this alteration, they hope to enable the immune cells to “see” and target the cancerous tissues effectively.
Dr. Seth Coffelt, the head of the research team, explained that cancer cells try to trick the immune cells into not perceiving them as a threat. When the immune cells become “blind” to the presence of cancer, the body’s defense mechanisms start to fail, leading to the progression of the disease.
Colon cancer is a significant global health issue, with over 1.9 million new cases reported in 2020 and more than 930,000 deaths worldwide. The findings of this study have been published in the “Cancer Immunology Research” journal of the American Cancer Research Association.
This research provides valuable insights into the mechanisms of colon cancer and opens up opportunities for developing more effective treatments. With further advancements in this field, it is hoped that better outcomes and survival rates can be achieved for individuals affected by colon cancer.
